Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 2 9Phase 3 7Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Recurrence 2Melanoma 2Peritoneal Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 31Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 15Biopsy 11trametinib 10dabrafenib 10fludarabine phosphate 9spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × Introns × Clear all
NCT01743157 2013-08-29

BBI

California Pacific Medical Center Research Institute

Phase 1/2 Completed
24 enrolled
Dermatologic

Melanoma

NCT01409187 2012-01-26

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡